TP53 and head and neck squamous cell carcinoma: In our recently reported phase-2 multi-institutional adjuvant trial with everolimus in stage IV HNSCC patients at high risk for recurrence, treatment with everolimus demonstrated significant improvement in 2-year progression-free survival (PFS) in patients with TP53 mutations compared to the placebo group [13].